{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T18:35:44Z","timestamp":1788028544881,"version":"build-2784847793"},"reference-count":31,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T00:00:00Z","timestamp":1680307200000},"content-version":"am","delay-in-days":335,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1016\/j.ejca.2022.02.024","type":"journal-article","created":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T13:27:53Z","timestamp":1648819673000},"page":"42-53","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs"],"prefix":"10.1016","volume":"167","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9120-8269","authenticated-orcid":false,"given":"Emeline","family":"Guiard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0604-7614","authenticated-orcid":false,"given":"Capucine","family":"Baldini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9dric","family":"Pobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tarek","family":"Assi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Bernard-Tessier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6444-348X","authenticated-orcid":false,"given":"Patricia","family":"Martin-Romano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5694-4022","authenticated-orcid":false,"given":"Lo\u00efc","family":"Verlingue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Geraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marie","family":"Michot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Armand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Massard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samy","family":"Ammari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejca.2022.02.024_bib1","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13045-019-0779-5","article-title":"Immune checkpoint inhibitors of PD-L1 as cancer therapeutics","volume":"12","author":"Akinleye","year":"2019","journal-title":"J Hematol Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2022.02.024_bib2","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1158\/1535-7163.MCT-09-0280","article-title":"Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts","volume":"8","author":"Roland","year":"2009","journal-title":"Mol Cancer Therapeut"},{"issue":"18","key":"10.1016\/j.ejca.2022.02.024_bib3","doi-asserted-by":"crossref","first-page":"5449","DOI":"10.1158\/1078-0432.CCR-18-1543","article-title":"The intersection between tumor angiogenesis and immune suppression","volume":"25","author":"Rahma","year":"2019","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2022.02.024_bib4","doi-asserted-by":"crossref","first-page":"12624","DOI":"10.1038\/ncomms12624","article-title":"Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma","volume":"7","author":"Wallin","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ejca.2022.02.024_bib5","doi-asserted-by":"crossref","DOI":"10.1186\/s12943-019-0974-6","article-title":"Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment","volume":"18","author":"Yi","year":"2019","journal-title":"Mol Cancer"},{"issue":"12","key":"10.1016\/j.ejca.2022.02.024_bib6","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1007\/s00432-019-03044-5","article-title":"Preclinical rationale and clinical efficacy of antiangiogenic therapy and immune checkpoint blockade combination therapy in urogenital tumors","volume":"145","author":"Zhu","year":"2019","journal-title":"J Cancer Res Clin Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2022.02.024_bib7","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.ejca.2022.02.024_bib8","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJMoa2035716","article-title":"Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma","volume":"384","author":"Motzer","year":"2021","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ejca.2022.02.024_bib9","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"15_suppl","key":"10.1016\/j.ejca.2022.02.024_bib10","article-title":"Adaptation and modification of the immune related response criteria (IRRC): IrRECIST","volume":"32","author":"Bohnsack","year":"2014","journal-title":"J Clin Orthod"},{"issue":"3","key":"10.1016\/j.ejca.2022.02.024_bib11","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1016\/S1470-2045(17)30074-8","article-title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","volume":"18","author":"Seymour","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.02.024_bib12","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1200\/EDBK_200643","article-title":"Patterns of response and progression to immunotherapy","volume":"38","author":"Borcoman","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"6","key":"10.1016\/j.ejca.2022.02.024_bib13","doi-asserted-by":"crossref","DOI":"10.1038\/sj.bjc.6604218","article-title":"Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience","volume":"98","author":"Arkenau","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2022.02.024_bib14","article-title":"Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)","year":"2017","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2022.02.024_bib15","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1001\/jamaoncol.2017.4771","article-title":"Association of the lung immune prognostic index with immune checkpoint inhibitor outcomes in patients with advanced non-small cell lung cancer","volume":"4","author":"Mezquita","year":"2018","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.ejca.2022.02.024_bib16","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/s41571-018-0111-2","article-title":"Hyperprogressive disease: recognizing a novel pattern to improve patient management","volume":"15","author":"Champiat","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.ejca.2022.02.024_bib17","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1093\/annonc\/mdz003","article-title":"Novel patterns of response under immunotherapy","volume":"30","author":"Borcoman","year":"2019","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.02.024_bib18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s00262-020-02647-z","article-title":"Patterns of progression in patients treated for immuno-oncology antibodies combination","volume":"70","author":"Bernard-Tessier","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"10.1016\/j.ejca.2022.02.024_bib19","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1007\/s00262-008-0642-y","article-title":"Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases","volume":"58","author":"Di Giacomo","year":"2009","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.ejca.2022.02.024_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1634\/theoncologist.2016-0150","article-title":"Mixed responses to systemic therapy revealed potential genetic heterogeneity and poor survival in patients with non-small cell lung cancer","volume":"22","author":"Dong","year":"2017","journal-title":"The Oncologist"},{"issue":"7467","key":"10.1016\/j.ejca.2022.02.024_bib21","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/nature12626","article-title":"Influence of tumour micro-environment heterogeneity on therapeutic response","volume":"501","author":"Junttila","year":"2013","journal-title":"Nature"},{"issue":"15","key":"10.1016\/j.ejca.2022.02.024_bib22","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1158\/1078-0432.CCR-16-3133","article-title":"Hyperprogressors after immunotherapy: analysis of genomic alterations associated with accelerated growth rate","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.ejca.2022.02.024_bib23","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1093\/annonc\/mdx178","article-title":"Hyperprogression during anti-PD-1\/PD-L1 therapy in patients with recurrent and\/or metastatic head and neck squamous cell carcinoma","volume":"28","author":"Sa\u00e2da-Bouzid","year":"2017","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ejca.2022.02.024_bib24","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1158\/1078-0432.CCR-16-1741","article-title":"Hyperprogressive disease is a new pattern of progression in cancer patients treated by anti-PD-1\/PD-L1","volume":"23","author":"Champiat","year":"2017","journal-title":"Clin Cancer Res"},{"issue":"13","key":"10.1016\/j.ejca.2022.02.024_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21134778","article-title":"Tumors resistant to checkpoint inhibitors can become sensitive after treatment with vascular disrupting agents","volume":"21","author":"Horsman","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ejca.2022.02.024_bib26","doi-asserted-by":"crossref","first-page":"e000146","DOI":"10.1136\/jitc-2019-000146","article-title":"Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis","volume":"8","author":"Mulkey","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.ejca.2022.02.024_bib27","doi-asserted-by":"crossref","first-page":"e001343","DOI":"10.1136\/jitc-2020-001343","article-title":"Novel, non-invasive imaging approach to identify patients with advanced non-small cell lung cancer at risk of hyperprogressive disease with immune checkpoint blockade","volume":"8","author":"Vaidya","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2022.02.024_bib28","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1158\/2326-6066.CIR-19-0476","article-title":"Changes in CT radiomic features associated with lymphocyte distribution predict overall survival and response to immunotherapy in non-small cell lung cancer","volume":"8","author":"Khorrami","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"9","key":"10.1016\/j.ejca.2022.02.024_bib29","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1016\/S1470-2045(18)30413-3","article-title":"A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study","volume":"19","author":"Sun","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2022.02.024_bib30","doi-asserted-by":"crossref","DOI":"10.1007\/s00330-021-07732-0","article-title":"Simultaneously acquired PET and ASL imaging biomarkers may be helpful in differentiating progression from pseudo-progression in treated gliomas","author":"Pellerin","year":"2021","journal-title":"Eur Radiol"},{"issue":"2","key":"10.1016\/j.ejca.2022.02.024_bib31","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11020348","article-title":"Heterogeneous response to immunotherapy in a patient with tonsillar squamous cell carcinoma assessed by 18F-FDG PET\/CT","volume":"11","author":"Niccoli Asabella","year":"2021","journal-title":"Diagnostics"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922001228?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922001228?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:36:11Z","timestamp":1760733371000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922001228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":31,"alternative-id":["S0959804922001228"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.02.024","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Radiological patterns of tumour progression in patients treated with a combination of immune checkpoint blockers and antiangiogenic drugs","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.02.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}